BRCA2 mutationAPCGenetic testingWhole-genome sequencingBreast cancerRenal cell carcinomaLiposarcomaMyeloproliferative neoplasiaBRCA2 germline mutations are known to predispose carriers to various cancer types, including breast, ovarian, pancreatic and prostate cancer. An association with melanoma has also been ...
BRCA2, which maps to chromosome 13q12–13, is another candidate tumour suppressor gene[67]. Germline mutations in this gene account for a large proportion of hereditary breast cancer families. An excessive number of SCCHN cases have been reported inBRCA2mutation carriers from several such families...
Excluding Ashkenazi founder mutation carriersb BRCA1 Age 19–64 yr 262 1535.8 5 3.26 (1.34–7.89) 1.64 3.05 (1.26–7.40) 8.2 (3.5–19) Age 65–84 yr 134 623.6 7 11.2 (5.34–23.6) 4.14 1.69 (0.80–3.56) 27 (15–47) Overall 332 2159.3 12 5.56 (3.15–9.81) 5.78 2.08 (1.17–3.68)...
The article discusses a study on the association of any exposure to chest -rays with an increased risk of breast cancer. It references to a study by N. Andrieu et al published in the "Jour...
Here, we apply a novel strategy using a case-only GWAS design51,52, in which SNP genotype frequencies in 7,257BRCA1and 5,097BRCA2mutation carrier BC cases are compared to those in 60,212 BC cases from the Breast Cancer Association Consortium (BCAC), unselected for mutation status. We ai...
Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study This study prospectively evaluated the utilization of cancer risk management strategies in a multi-institutional cohort of BRCA1 and BRCA2 mutation carrier... KA Phillips,MA ...
It was not necessary to be a proven carrier of the mutation found in the family to be included in the study; however, affected women who were known to be non-carriers were excluded. All study procedures were approved by the Institutional Review Boards at each of the participating centres. ...
It was not necessary to be a proven carrier of the family mutation to be included in the study; however, affected women who were known to be noncarriers were excluded. All study procedures were approved by the institutional review boards at each of the participating centers. All participants ...
Several empiric and computer-based risk assessment models have been developed to estimate a counselee's probability of being a carrier of mutation in BRCA1 and/or 2 genes, and to predict the risk of developing breast cancer. The COS model was developed from the better-known BRCAPro model to...
关键词: Breast Cancer Breast Cancer BRCA2 Mutation Breast Cancer Incidence BRCA2 Mutation Carrier DOI: 10.1245/s10434-015-4532-1 被引量: 14 年份: 2015 收藏 引用 批量引用 报错 分享 全部来源 求助全文 Springer dx.doi.org NCBI NCBI Europe PMC 查看更多 相似文献 参考文献 引证文献...